Ethicon Endo-Surgery Targets Impact Of Metabolic and Bariatric Surgery on Diabetes
(PRNewswire) The science of obesity is undergoing a revolution, as new research changes the way scientists think about how and why metabolic and bariatric surgery works. Ethicon Endo-Surgery is helping drive that revolution by supporting clinical and pre-clinical research, including 13 studies being presented at the American Diabetes Association's (ADA) 72nd Scientific Sessions in Philadelphia (June 8-12). The studies investigate a range of cutting-edge approaches to metabolic and bariatric surgery and evolve the current understanding of the mechanisms of action as a key means to finding new, more effective interventions for obesity, diabetes and other metabolic disorders.
These studies are part of the EES Metabolic Applied Research Strategy (MARS), an ongoing initiative which aims to deconstruct, understand and reinvent metabolic and bariatric surgical procedures in ways that deliver less invasive options. Experts now recognize that surgical manipulation of tissue in the gastrointestinal tract induces physiological responses that can address metabolic abnormalities associated with Type 2 diabetes, obesity, hyperlipidemia and other metabolic disorders.
MARS examines each specific part of the surgical process to understand the cascade of biological signals that it triggers and determine the processes which have the greatest impact. Specifically, studies presented at ADA look at the role of gut hormones on therapeutic outcomes after surgery, and the impact of metabolic and bariatric surgery on the incretin system and lipid metabolism. The studies will help inform as to which patients will receive the most benefit from individual procedures; how steps can be taken to minimize adverse events; and how targeted interventions can preferentially treat metabolic disorders.
Obesity is a life-threatening condition affecting more than one-third of adults in the United States, and is associated with more than 30 illnesses and medical conditions, including type 2 diabetes, coronary heart disease, stroke, hypertension, sleep apnea, osteoarthritis and cancer. EES is funding research with the aim of changing the conversation about bariatric surgery and weight loss to metabolic surgery and co-morbid condition resolution. This evolution has been reinforced by recent data from the STAMPEDE (Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently) trial which indicates that overweight, diabetic patients who underwent surgery (gastric bypass and sleeve gastrectomy) achieved significant improvement or remission of their diabetes. The research is being conducted by the Cleveland Clinic.